Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
about
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistanceCYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma.Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsCytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention.Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers.CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Aberrant DNA Methylation: Implications in Racial Health Disparity.CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance.Electrochemiluminescent arrays for cytochrome P450-activated genotoxicity screening. DNA damage from benzo[a]pyrene metabolitesCytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancerCYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic CaucasiansA new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallateCancer treatment: the combination of vaccination with other therapies.A suite of activity-based probes for human cytochrome P450 enzymes.Tumor microsomal metabolism of the food toxicant, benzo(a)pyrene, in ApcMin mouse model of colon cancer.Biological basis of cancer health disparities: resources and challenges for research.Therapeutic cancer vaccines in combination with conventional therapy.Cytochrome P450-activated prodrugs.The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4Cytochrome P450 CYP1B1 activity in renal cell carcinoma.Potential role of CYP1B1 in the development and treatment of metabolic diseases.Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents.Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study.GPER is involved in the regulation of the estrogen-metabolizing CYP1B1 enzyme in breast cancer.Structure-Based Design and Synthesis of New Estrane-Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors.
P2860
Q28538733-142801DB-4F0C-4A3E-9BBD-567575DEBB53Q30440774-CCF70E85-8B65-4C8A-8EF1-8E3C4EC843ECQ31155554-83AEFA71-68BD-4851-AE7D-0FC0B5C94F85Q33393174-E3861238-1FF7-416A-9A7B-FBF5794E0FE0Q33704464-9F66D64C-EAB2-41DE-A422-620B55CB051CQ33771427-550657C6-CAB7-44D7-B741-816A947AA4EDQ34273137-8778F63D-9D08-44FE-828D-C73338852444Q34936845-B9B2D24F-33AB-4AE3-9C63-6771D28E0236Q35291824-385B6F63-5E6E-4544-8B53-C8ECD8990142Q35781414-5C64D29E-23CB-4CEA-A3B8-53B002317779Q35966821-2488C501-0644-4C76-8C6E-92DA8583F6A8Q35998173-4BC26351-1884-4C9F-9E1E-41EAF39065D9Q36459804-CB971224-6F80-468B-A72B-34E9449CAB55Q36571491-A662E292-3A1B-4F91-8441-B0042636AF22Q36623452-9212C129-F137-4D22-A307-E1F70C1532EAQ36857575-A94C66CA-27DE-418C-BC58-B2077AE43000Q36935966-800417B1-AF0C-4397-A2AD-F88BB0F48D25Q37089001-4F1BE271-C5BA-425F-9E90-F68616D2287BQ37331285-854C0D25-F893-4FFC-811E-3FEACA3951E5Q37467514-79EB6B9D-8C4B-4C49-8CD4-E61B3CBD672FQ37596808-017C418A-FC57-43D3-BB19-58308FD3723FQ37771267-DD432560-C2FB-486C-BFEF-67DD224BB9A6Q38077550-6C0DE59A-7A65-40E7-8611-FFD331ACA887Q38749517-016D95A5-3F72-495F-B609-0DC5EFD5E5A1Q38800931-DCAF704F-EBB4-4E36-BB4D-08D84FD5CE45Q39189895-68402571-37B1-480D-B639-BFD2F7CA7774Q41935784-A3A02F8B-33F2-48A5-8B4A-BCE57D3A3AFBQ41991645-2C29715F-52E8-4777-9646-52ABF155653AQ47227722-71B724B0-9CDA-42B2-92B0-95C6CDB0CF4FQ48597139-1286032A-1E72-41B6-8A2D-3F43FE6C75EB
P2860
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@ast
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@en
type
label
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@ast
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@en
prefLabel
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@ast
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@en
P2093
P1476
Human CYP1B1 and anticancer ag ...... or-specific drug inactivation?
@en
P2093
P304
P407
P577
2001-02-01T00:00:00Z